Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam.
暂无分享,去创建一个
[1] Sara K Quinney,et al. Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite , 2009, Drug Metabolism and Disposition.
[2] Kairui Feng,et al. The Simcyp® Population-based ADME Simulator , 2009 .
[3] Z. Barter,et al. Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.
[4] Masoud Jamei,et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. , 2008, Current drug metabolism.
[5] Masoud Jamei,et al. Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.
[6] Caroline A. Lee,et al. Sequential Metabolism Is Responsible for Diltiazem-Induced Time-Dependent Loss of CYP3A , 2007, Drug Metabolism and Disposition.
[7] Malcolm Rowland,et al. Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.
[8] Karthik Venkatakrishnan,et al. Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.
[9] Amir Heydari,et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA , 2006, Journal of psychopharmacology.
[10] G. Tucker,et al. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[11] Amin Rostami-Hodjegan,et al. Changes in liver volume from birth to adulthood: A meta‐analysis , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[12] Kiyomi Ito,et al. CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions , 2005, Journal of Pharmacology and Experimental Therapeutics.
[13] Caroline A. Lee,et al. EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES , 2005, Drug Metabolism and Disposition.
[14] Aleksandra Galetin,et al. UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES , 2004, Drug Metabolism and Disposition.
[15] Amin Rostami-Hodjegan,et al. Cytochrome P450 3A expression and activity in the human small intestine , 2004, Clinical pharmacology and therapeutics.
[16] Yvonne S. Lin,et al. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[17] Oliver Burk,et al. Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.
[18] Amin Rostami-Hodjegan,et al. The effects of dose staggering on metabolic drug-drug interactions. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[19] D. Greenblatt,et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice , 2003, Clinical pharmacology and therapeutics.
[20] Kiyomi Ito,et al. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[21] Scott L Cockroft,et al. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[22] E. Molden,et al. Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype , 2002, Clinical pharmacology and therapeutics.
[23] K. Yeo,et al. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. , 2001, British journal of clinical pharmacology.
[24] S D Hall,et al. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[25] P. Neuvonen,et al. Effect of grapefruit juice dose on grapefruit juice–triazolam interaction: repeated consumption prolongs triazolam half-life , 2000, European Journal of Clinical Pharmacology.
[26] S. Hall,et al. The interaction of diltiazem with simvastatin , 2000, Clinical pharmacology and therapeutics.
[27] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[28] D. Jones,et al. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. , 1999, The Journal of pharmacology and experimental therapeutics.
[29] G. Tucker,et al. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. , 1999, British journal of clinical pharmacology.
[30] D. Greenblatt,et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences , 1998, Clinical pharmacology and therapeutics.
[31] Y. Sugiyama,et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.
[32] E. Steiner,et al. Time course of enzyme induction in humans: Effect of pentobarbital on nortriptyline metabolism , 1998, Clinical pharmacology and therapeutics.
[33] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[34] M. Murray,et al. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.
[35] J. Leonard,et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects , 1997, Antimicrobial agents and chemotherapy.
[36] P. Maurel. The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man , 1996 .
[37] M. Fromm,et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin , 1996, Hepatology.
[38] R. Davies,et al. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine , 1996, Clinical pharmacology and therapeutics.
[39] P. Neuvonen,et al. Diltiazem enhances the effects of triazolam by inhibiting its metabolism , 1996, Clinical pharmacology and therapeutics.
[40] D E Salazar,et al. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. , 1995, Journal of clinical psychopharmacology.
[41] P. Kroboth,et al. Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. , 1995, Journal of clinical psychopharmacology.
[42] R B Smith,et al. Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. , 1995, Journal of clinical psychopharmacology.
[43] P. Neuvonen,et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. , 1994, British journal of clinical pharmacology.
[44] M. Quilliam,et al. Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose , 1993, European Journal of Drug Metabolism and Pharmacokinetics.
[45] C. Bonfils,et al. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[46] K. Giacomini,et al. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose , 1989, Clinical pharmacology and therapeutics.
[47] L. Nilsson,et al. Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. , 1989, Therapeutic drug monitoring.
[48] A. Fraser. Urinary screening for alprazolam, triazolam, and their metabolites with the EMIT d.a.u. benzodiazepine metabolite assay. , 1987, Journal of analytical toxicology.
[49] D. Abernethy,et al. N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. , 1987, British journal of clinical pharmacology.
[50] D. Greenblatt,et al. Population study of triazolam pharmacokinetics. , 1986, British journal of clinical pharmacology.
[51] P. Kroboth,et al. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics , 1984, Clinical pharmacology and therapeutics.
[52] H. Ochs,et al. Pharmacokinetics and absolute bioavailability of diltiazem in humans , 1984, Klinische Wochenschrift.
[53] D. Greenblatt,et al. Concentration‐independent plasma protein binding of benzodiazepines , 1983, The Journal of pharmacy and pharmacology.
[54] D. Greenblatt,et al. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. , 1983, British journal of clinical pharmacology.
[55] R. Cutler,et al. Time‐course of interaction between carbamazepine and clonazepam in normal man , 1978, Clinical pharmacology and therapeutics.
[56] D. London,et al. Pharmacokinetics of diltiazem after intravenous and oral administration , 2004, European Journal of Clinical Pharmacology.
[57] C. Regårdh,et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects , 2004, European Journal of Clinical Pharmacology.
[58] A. Åsberg,et al. Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[59] Y. Sawada,et al. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. , 2000, British journal of clinical pharmacology.
[60] J. Smith,et al. Comparison of rubidium-86 and potassium-42 fluxes in rat aorta. , 1986, Blood vessels.
[61] Kölle Eu,et al. Pharmacokinetic model of diltiazem. , 1983 .